Article Data

  • Views 372
  • Dowloads 138

Original Research

Open Access Special Issue

Association of anemia and neutrophil-lymphocyte ratio with overall survival in breast cancer patients

  • Rafael de Carvalho da Silva1
  • Raphael Elias Ferreira1
  • Tatiana Castrillon Guaresqui1
  • Lúcia Marina Scatena2
  • Beatriz Martins Tavares-Murta3
  • Eddie Fernando Candido Murta1
  • Rosekeila Simões Nomelini1,*,

1Department of Gynecology and Obstetrics, Federal University of Triângulo Mineiro (UFTM), 38025-440 Uberaba-MG, Brazil

2Department of Collective Health, Federal University of Triângulo Mineiro (UFTM), 38025-440 Uberaba-MG, Brazil

3Discipline of Pharmacology, Federal University of Triângulo Mineiro (UFTM), 38025-440 Uberaba-MG, Brazil

DOI: 10.22514/ejgo.2022.014 Vol.43,Issue 3,June 2022 pp.97-102

Submitted: 23 January 2022 Accepted: 13 April 2022

Published: 15 June 2022

(This article belongs to the Special Issue Prognosis and Treatment of Breast Cancer)

*Corresponding Author(s): Rosekeila Simões Nomelini E-mail: rosekeila@terra.com.br; rosekeila.nomelini@pesquisador.cnpq.br

Abstract

Objective: The neutrophil-lymphocyte ratio (NLR) has been shown to correlate with disease progression and survival in a number of cancers. In this study we explore this ratio and a number of other blood-derived factors, including platelet-lymphocyte ratio (PLR) and hemoglobin levels, for their prognostic value with overall survival in breast cancer patients. Methods: A retrospective study was conducted with data from the medical records of patients with breast cancer (n = 303) collected from a breast cancer treatment and research clinic. The data included clinical staging at diagnosis, tumor size, axillary lymph node involvement, presence or absence of metastases, tumor histology, tumor grade, hormone receptor, treatments received (surgery, chemotherapy, hormonotherapy), overall survival, NLR, PLR, anemia, leukocytosis, neutrophilia, and lymphopenia. Cox regression was used to verify the influence of the variables on five-year overall survival of patients following their initial diagnosis. Results: Patients with NLR >4 showed association with staging >II (p < 0.05), with the presence of metastasis (p < 0.0001), and with negative hormone receptor (p < 0.0001). A hemoglobin <12 g/dL associated with staging >II (p < 0.0001), with the presence of metastasis (p < 0.0001), and with negative hormone receptor (p < 0.05). High values of NLR and PLR were associated with shorter overall survival by Kaplan-Meier survival curves (p < 0.001 and p = 0.021, respectively). After multivariate regression, tumor size, lymph node status, metastasis, NLR and anemia remained as factors that independently influenced mortality at 5 years. NLR >4 increased the risk of death by 7.76 times (p < 0.001) and hemoglobin <12 mg/d increased the risk of death by 2.47 times (p = 0.037). Conclusions: NLR and anemia are factors that independently correlate with overall survival in breast cancer patients. These factors have the advantage of being derived from simple and inexpensive blood testing.


Keywords

Neutrophil-lymphocyte ratio; Anemia; Hemoglobin; Overall survival; Breast cancer


Cite and Share

Rafael de Carvalho da Silva,Raphael Elias Ferreira,Tatiana Castrillon Guaresqui,Lúcia Marina Scatena,Beatriz Martins Tavares-Murta,Eddie Fernando Candido Murta,Rosekeila Simões Nomelini. Association of anemia and neutrophil-lymphocyte ratio with overall survival in breast cancer patients. European Journal of Gynaecological Oncology. 2022. 43(3);97-102.

References

[1] International Agency for Research on Cancer (IARC). Cancer causes. 2020. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf (Accessed: 24 October 2021).

[2] Brazil. Ministerio da Saúde. Estimativa 2021: incidência de câncer no Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva. 2021. Available at: https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama (Accessed: 24 October 2021).

[3] Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Research and Treatment. 2008; 107: 309–330.

[4] Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treatment Reviews. 2001; 27: 137–142.

[5] Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an um-brella review of systematic reviews and meta-analyses of observational studies. BMC Medicine. 2020; 18: 360.

[6] Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surgical Oncology. 2014; 23: 31–39.

[7] Koh C, Bhoo-Pathy N, Ng K, Jabir RS, Tan G, See M, et al. Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. British Journal of Cancer. 2015; 113: 150–158.

[8] Ethier J, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research. 2017; 19: 2.

[9] Krenn-Pilko S, Langsenlehner U, Thurner E, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. British Journal of Cancer. 2014; 110: 2524–2530.

[10] Zhang Y, Chen Y, Chen D, Jiang Y, Huang W, Ouyang H, et al. Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014; 14: 844.

[11] Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?International Journal of Clinical Oncology. 2015; 20: 70–81.

[12] Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Medical Oncology. 2013; 30: 432.

[13] Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences. 2001; 98: 10869–10874.

[14] Zhu Y, Si W, Sun Q, Qin B, Zhao W, Yang J. Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. Oncotarget. 2017; 8: 1023–1030.

[15] Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS ONE. 2014; 9: e101119.

[16] Kandemir E, Mayadagli A, Turken O, Yaylaci M, Ozturk A. Pre-treatment Haemoglobin Concentration is a Prognostic Factor in Patients with Early-stage Breast Cancer. Journal of International Medical Research. 2005; 33: 319–328.

[17] Lee C, Tsai C, Yeh D, Lin C, Li Y, Tzeng H. Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer. Oncotarget. 2016; 8: 1569–1579.

[18] Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, et al. Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer. 2013; 13: 340.

[19] Eichbaum MH, Weiss LM, Bruckner T, Schneeweiss A, Sinn HP, Gebauer G, et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane- based chemotherapy in patients with primary invasive epithelial ovarian cancer. Medical Science Monitor. 2009; 15: CR156–CR163.

[20] Pongsanon K, Benjapibal M, Ruengkhachorn I. Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinumbased chemotherapy. Asian Pacific Journal of Cancer Prevention. 2011; 12: 131–136.

[21] Nomelini RS, de Carvalho Oliveira LJ, Tavares-Murta BM, Murta EFC. Parameters of blood count and tumor markers: a retrospective analysis and relation to prognostic factors in ovarian cancer. European Journal of Gynaecological Oncology. 2017; 38: 364–367.

[22] Nomelini RS, da Silva TM, Tavares Murta BM, Murta EFC. Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: a Retrospective Analysis and Relation to Staging. ISRN Oncology. 2012; 2012: 947831.

[23] Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate study of the prognosis of oral squamous cell carcinomas. are blood group and hemoglobin new prognostic factors? Cancer. 1991; 68: 1994–1998.

[24] Zhu W, Xu B. Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: a population-based study. PLoS ONE. 2015; 10: e0136268.

[25] Lamy P, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer. Clinica Chimica Acta. 2014; 434: 34–40.

[26] Candido J, Hagemann T. Cancer-Related Inflammation. Journal of Clinical Immunology. 2013; 33: 79–84.

[27] Bailur JK, Pawelec G, Hatse S, Brouwers B, Smeets A, Neven P, et al. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Research. 2017; 19: 20.

[28] Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nature Reviews Cancer. 2016; 16: 431–446.

[29] Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature Reviews Cancer. 2011; 11: 123–134.

[30] Criscitiello C, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treatment Reviews. 2016; 50: 205–207.

[31] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436–444.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top